

Saturday 14 March 2009 - Morning

	Pearl A	Crystal Room	Pearl C
09:00	<p>DEBATES</p> <p>Co-chair: M. Borggreffe (Ger) W. Haddad (Leb)</p> <p>Echo is mandatory in patient selection for CRT Pro W. Jaber (USA) Con J. Kautzner (Czech republic)</p> <p>All patients with EF <35% should receive an ICD Pro P. Milliez (France) Con F. Legal (France)</p> <p>AAI is better than DDD in patients with sinus node dysfunction Pro M. Santini (Italy) Con Ph. Ritter (France)</p>	<p>"CARDIOPACE": WHEN DO WE NEED A SURGEON? In collaboration with the Lebanese Society of cardiothoracic surgery</p> <p>Co-chair: P. Karam (Leb) F. Zankoul (Leb)</p> <p>Place of thoracoscopy in management of persistent atrial fibrillation L. de Roy (Belgium)</p> <p>CRT implantation failure: How can the surgeon be of help? R. Ashoush (Lebanon)</p> <p>Resynchronizing the heart after surgery for congenital HD R. Hneine (France)</p> <p>Surgical endoscopic resynchronization with robot Da Vinci F. Farhat (France)</p>	<p>MYOCARDIAL INFARCTION AND HEART FAILURE AT THE CROSS-ROAD</p> <p>Co-chair:</p> <p>Diagnostic and prognostic value of BNP and pro-BNP R. Kassab (Lebanon)</p> <p>Evaluation of Right Ventricular Function Joe Maalouf (USA)</p> <p>Role of Omega 3 fatty acids in the genesis of arrhythmia in MI and HF H. Rupp (Germany)</p> <p>Rethinking heart failure after GISSI-HF M. Khoury (UAE)</p> <p style="color: blue;">with an educational grant from Solvay Pharmaceuticals</p>
10:30	Break	Break	Break
11:00	<p>PREVENTION OF AF: AN EVIDENCE-BASED APPROACH</p> <p>Co-chair: Z. Smiri (Tun) W. Khoury (Leb)</p> <p>Antiarrhythmic agents for the prevention of paroxysmal and persistent AF H. Rizk (Egypt)</p> <p>Supportive therapy for AF: Statins, ACEI, ARB'S, Omega3, Magnesium M. Borggreffe (Germany)</p> <p>Can we prevent AF by pacing? M. Santini (Italy)</p> <p>Can Mitral valve repair prevent AF? V. Gebara (Lebanon)</p>	<p>WORKSHOP: MEET THE EXPERTS</p> <p>FROM PILL TO WIRE IN THE MANAGEMENT OF VENTRICULAR TACHYCARDIA</p> <p>Co-chair: H. Zouzou (Alg) S. Rafla (Egy)</p> <p>How to diagnose a wide QRS tachycardia? N. Al Rawahi (Oman)</p> <p>Drug therapy to prevent VT JM Davy (France)</p> <p>Ablation of VT: Case reports L. De Roy (Belgium)</p> <p>ICD's: ATP versus Shock M. Khoury (Lebanon)</p>	<p>THE SECOND POST-CONGRESS WORKSHOP ON MANAGEMENT OF CV RISK FACTORS Endorsed by the International task force for prevention of CHD and the Lebanese society of atherosclerosis on invitation by Phénicia</p> <p>1. ATHEROSCLEROSIS: RISK FACTORS AND RISK MARKERS</p> <p>Co-chair:</p> <p>Risk stratification in atherosclerosis: Lessons from the PROCAM study G. Assmann (Germany)</p> <p>How can CT scan add to the risk stratification W. Jaber (USA)</p> <p>Old and new Markers for coronary artery disease R. Azar (Lebanon)</p> <p>Kidney disease as a cardiovascular risk factor A. Barbari (Lebanon)</p>
12:30	Closing	Closing	Coffee Break
13:30			<p>2. ATHEROSCLEROSIS: THERAPEUTIC CONSIDERATION</p> <p>Co-chair:</p> <p>Management of Dyslipidemia in the post-MI W. Riesen (Switzerland)</p> <p>Targets in the management of diabetes I. Salti (Lebanon)</p> <p>Atherothrombosis: benefit of anti-platelet therapy K. Khalifé (France)</p> <p>Management of microalbuminuria: Evidence for Sulodexide A. Barbari (Lebanon)</p>
15:00			